Limits...
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.

Dalal P, Grafals M, Chhabra D, Gallon L - Ther Clin Risk Manag (2009)

Bottom Line: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH).It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses.Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mount Sinai Hospital, Chicago, USA;

ABSTRACT
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses. Clinical trials in kidney transplant recipients have shown the efficacy of MMF in reducing the incidence and severity of acute rejection episodes. It also improves long term graft function as well as graft and patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

No MeSH data available.


Related in: MedlinePlus

Chemical structure of mycophenolate mofetil (MMF) – the morpholinoethyl ester of mycophenolic acid (MPA) – mycophenolate.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2697521&req=5

f1-tcrm-5-0139: Chemical structure of mycophenolate mofetil (MMF) – the morpholinoethyl ester of mycophenolic acid (MPA) – mycophenolate.

Mentions: Mycophenolate mofetil (MMF) is an ester prodrug of mycophenolic acid (Figure 1). Mycophenolic acid (MPA) is a fermentation product of Penicillium brevicompactum and related fungi.1 It was discovered by Gosio in 1893 and was shown to have weak antibacterial activity.2 Its ability to inhibit inosine-5’-monophosphate dehydrogenase (IMPDH) was first identified in 1969.3 Initial studies with MMF in animal models of organ transplantation yielded encouraging results and led to the initiation of human trials.4,5 Sollinger et al conducted the first human trial of MMF in 1992 in kidney transplant recipients.6 Since then, MMF has been used in combination with other medications to prevent acute rejections, for rescue treatment in acute rejection episodes and as adjuvant to facilitate “sparing” of other immunosuppressive agents.


Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.

Dalal P, Grafals M, Chhabra D, Gallon L - Ther Clin Risk Manag (2009)

Chemical structure of mycophenolate mofetil (MMF) – the morpholinoethyl ester of mycophenolic acid (MPA) – mycophenolate.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2697521&req=5

f1-tcrm-5-0139: Chemical structure of mycophenolate mofetil (MMF) – the morpholinoethyl ester of mycophenolic acid (MPA) – mycophenolate.
Mentions: Mycophenolate mofetil (MMF) is an ester prodrug of mycophenolic acid (Figure 1). Mycophenolic acid (MPA) is a fermentation product of Penicillium brevicompactum and related fungi.1 It was discovered by Gosio in 1893 and was shown to have weak antibacterial activity.2 Its ability to inhibit inosine-5’-monophosphate dehydrogenase (IMPDH) was first identified in 1969.3 Initial studies with MMF in animal models of organ transplantation yielded encouraging results and led to the initiation of human trials.4,5 Sollinger et al conducted the first human trial of MMF in 1992 in kidney transplant recipients.6 Since then, MMF has been used in combination with other medications to prevent acute rejections, for rescue treatment in acute rejection episodes and as adjuvant to facilitate “sparing” of other immunosuppressive agents.

Bottom Line: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH).It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses.Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mount Sinai Hospital, Chicago, USA;

ABSTRACT
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses. Clinical trials in kidney transplant recipients have shown the efficacy of MMF in reducing the incidence and severity of acute rejection episodes. It also improves long term graft function as well as graft and patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

No MeSH data available.


Related in: MedlinePlus